Castle Biosciences To Present New Data On DecisionDx-Melanoma At EADV Congress 2026

Castle Biosciences, Inc. (Nasdaq: CSTL) will present new findings on DecisionDx-Melanoma at the EADV Congress 2026, highlighting that patients with low-risk results had sentinel lymph node positivity below 5% and a five-year recurrence-free survival rate of 99.6% for those who avoided sentinel lymph node biopsy. Additionally, a separate ePoster indicates that DecisionDx-Melanoma can identify early-stage melanomas with recurrence risks similar to stage IIB, suggesting a need for closer surveillance in uncertain staging cases. The study involved 2,799 patients across 29 U.S. centers, marking the largest prospective, multi-center study of gene expression profiling in cutaneous melanoma to date.